Global Microbiome Therapeutics Market Size, Manufacturers, Opportunities and Forecast to 2030

Global Microbiome Therapeutics Market Size, Manufacturers, Opportunities and Forecast to 2030


Summary

The human microbiome is the collection of all the microorganisms living in association with the human body. These communities consist of a variety of microorganisms including eukaryotes, archaea, bacteria and viruses. Bacteria in an average human body number ten times more than human cells, for a total of about 1000 more genes than are present in the human genome. Because of their small size, however, microorganisms make up only about 1 to 3 percent of our body mass (that's 2 to 6 pounds of bacteria in a 200-pound adult).
These microbes are generally not harmful to us; in fact they are essential for maintaining health. For example, they produce some vitamins that we do not have the genes to make, break down our food to extract nutrients we need to survive, teach our immune systems how to recognize dangerous invaders and even produce helpful anti-inflammatory compounds that fight off other disease-causing microbes.
An ever-growing number of studies have demonstrated that changes in the composition of our microbiomes correlate with numerous disease states, raising the possibility that manipulation of these communities could be used to treat disease.

According to APO Research, The global Microbiome Therapeutics market was estimated at US$ million in 2023 and is projected to reach a revised size of US$ million by 2030, witnessing a CAGR of xx% during the forecast period 2024-2030.

North American market for Microbiome Therapeutics is estimated to increase from $ million in 2024 to reach $ million by 2030, at a CAGR of % during the forecast period of 2025 through 2030.

Asia-Pacific market for Microbiome Therapeutics is estimated to increase from $ million in 2024 to reach $ million by 2030, at a CAGR of % during the forecast period of 2025 through 2030.

Europe market for Microbiome Therapeutics is estimated to increase from $ million in 2024 to reach $ million by 2030, at a CAGR of % during the forecast period of 2025 through 2030.

The major global companies of Microbiome Therapeutics include Seres Therapeutics, Assembly Biosciences, Synthetic Biologics, Interxon, PureTech, Synlogic, Enterome BioScience, 4D Pharma and Second Genome, etc. In 2023, the world's top three vendors accounted for approximately % of the revenue.

Report Scope

This report aims to provide a comprehensive presentation of the global market for Microbiome Therapeutics, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Microbiome Therapeutics.
The Microbiome Therapeutics market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Microbiome Therapeutics market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided. For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.

Key Companies & Market Share Insights

In this section, the readers will gain an understanding of the key players competing. This report has studied the key growth strategies, such as innovative trends and developments, intensification of product portfolio, mergers and acquisitions, collaborations, new product innovation, and geographical expansion, undertaken by these participants to maintain their presence. Apart from business strategies, the study includes current developments and key financials. The readers will also get access to the data related to global revenue, gross margin by manufacturers for the period 2019-2024. This all-inclusive report will certainly serve the clients to stay updated and make effective decisions in their businesses. Some of the prominent players reviewed in the research report include:

Seres Therapeutics
Assembly Biosciences
Synthetic Biologics
Interxon
PureTech
Synlogic
Enterome BioScience
4D Pharma
Second Genome
AOBiome
C3 Jian
Rebiotix
MicroBiome Therapeutics LLC
Metabiomics
Ritter Pharmaceuticals
Symberix
OpenBiome
Azitra
Symbiotix Biotherapies
Osel
Metabogen
Microbiome Therapeutics segment by Type

Upper GIT
Lower GIT
Microbiome Therapeutics segment by Application

C. difficile Infection (CDI)
Inflammatory Bowel Disease (IBD)
Orphan Drug
Immuno-oncology
Others
Microbiome Therapeutics Segment by Region

North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Indonesia
Thailand
Malaysia
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE

Key Drivers & Barriers

High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Microbiome Therapeutics market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Microbiome Therapeutics and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Microbiome Therapeutics.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of global and regional market size and CAGR for the history and forecast period (2019-2024, 2025-2030). It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 3: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 4: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 5: Detailed analysis of Microbiome Therapeutics companies' competitive landscape, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product introduction, revenue, recent development, etc.
Chapter 7, 8, 9, 10 and 11: North America, Europe, Asia Pacific, Latin America, Middle East & Africa, revenue by country.
Chapter 12: Concluding Insights of the report


1 Market Overview
1.1 Product Definition
1.2 Global Market Growth Prospects
1.3 Global Microbiome Therapeutics Market Size Overview by Region 2019 VS 2023 VS 2030
1.4 Global Microbiome Therapeutics Market Size by Region (2019-2030)
1.4.1 Global Microbiome Therapeutics Market Size by Region (2019-2024)
1.4.2 Global Microbiome Therapeutics Market Size by Region (2025-2030)
1.5 Key Regions Microbiome Therapeutics Market Size (2019-2030)
1.5.1 North America Microbiome Therapeutics Market Size Growth Rate (2019-2030)
1.5.2 Europe Microbiome Therapeutics Market Size Growth Rate (2019-2030)
1.5.3 Asia-Pacific Microbiome Therapeutics Market Size Growth Rate (2019-2030)
1.5.4 Latin America Microbiome Therapeutics Market Size Growth Rate (2019-2030)
1.5.5 Middle East & Africa Microbiome Therapeutics Market Size Growth Rate (2019-2030)
2 Microbiome Therapeutics Market by Type
2.1 Type Introduction
2.1.1 Upper GIT
2.1.2 Lower GIT
2.2 Global Microbiome Therapeutics Market Size by Type
2.2.1 Global Microbiome Therapeutics Market Size Overview by Type (2019-2030)
2.2.2 Global Microbiome Therapeutics Historic Market Size Review by Type (2019-2024)
2.2.3 Global Microbiome Therapeutics Market Size Forecasted by Type (2025-2030)
2.3 Global Microbiome Therapeutics Market Size by Regions
2.3.1 North America Microbiome Therapeutics Market Size Breakdown by Type (2019-2024)
2.3.2 Europe Microbiome Therapeutics Market Size Breakdown by Type (2019-2024)
2.3.3 Asia-Pacific Microbiome Therapeutics Market Size Breakdown by Type (2019-2024)
2.3.4 Latin America Microbiome Therapeutics Market Size Breakdown by Type (2019-2024)
2.3.5 Middle East and Africa Microbiome Therapeutics Market Size Breakdown by Type (2019-2024)
3 Microbiome Therapeutics Market by Application
3.1 Type Introduction
3.1.1 C. difficile Infection (CDI)
3.1.2 Inflammatory Bowel Disease (IBD)
3.1.3 Orphan Drug
3.1.4 Immuno-oncology
3.1.5 Others
3.2 Global Microbiome Therapeutics Market Size by Application
3.2.1 Global Microbiome Therapeutics Market Size Overview by Application (2019-2030)
3.2.2 Global Microbiome Therapeutics Historic Market Size Review by Application (2019-2024)
3.2.3 Global Microbiome Therapeutics Market Size Forecasted by Application (2025-2030)
3.3 Global Microbiome Therapeutics Market Size by Regions
3.3.1 North America Microbiome Therapeutics Market Size Breakdown by Application (2019-2024)
3.3.2 Europe Microbiome Therapeutics Market Size Breakdown by Application (2019-2024)
3.3.3 Asia-Pacific Microbiome Therapeutics Market Size Breakdown by Application (2019-2024)
3.3.4 Latin America Microbiome Therapeutics Market Size Breakdown by Application (2019-2024)
3.3.5 Middle East and Africa Microbiome Therapeutics Market Size Breakdown by Application (2019-2024)
4 Global Market Dynamics
4.1 Microbiome Therapeutics Industry Trends
4.2 Microbiome Therapeutics Industry Drivers
4.3 Microbiome Therapeutics Industry Opportunities and Challenges
4.4 Microbiome Therapeutics Industry Restraints
5 Competitive Insights by Company
5.1 Global Top Players by Microbiome Therapeutics Revenue (2019-2024)
5.2 Global Microbiome Therapeutics Industry Company Ranking, 2022 VS 2023 VS 2024
5.3 Global Microbiome Therapeutics Key Company Headquarters & Area Served
5.4 Global Microbiome Therapeutics Company, Product Type & Application
5.5 Global Microbiome Therapeutics Company Commercialization Time
5.6 Market Competitive Analysis
5.6.1 Global Microbiome Therapeutics Market CR5 and HHI
5.6.2 Global Top 5 and 10 Microbiome Therapeutics Players Market Share by Revenue in 2023
5.6.3 2023 Microbiome Therapeutics Tier 1, Tier 2, and Tier 3
6 Company Profiles
6.1 Seres Therapeutics
6.1.1 Seres Therapeutics Comapny Information
6.1.2 Seres Therapeutics Business Overview
6.1.3 Seres Therapeutics Microbiome Therapeutics Revenue, Global Share and Gross Margin (2019-2024)
6.1.4 Seres Therapeutics Microbiome Therapeutics Product Portfolio
6.1.5 Seres Therapeutics Recent Developments
6.2 Assembly Biosciences
6.2.1 Assembly Biosciences Comapny Information
6.2.2 Assembly Biosciences Business Overview
6.2.3 Assembly Biosciences Microbiome Therapeutics Revenue, Global Share and Gross Margin (2019-2024)
6.2.4 Assembly Biosciences Microbiome Therapeutics Product Portfolio
6.2.5 Assembly Biosciences Recent Developments
6.3 Synthetic Biologics
6.3.1 Synthetic Biologics Comapny Information
6.3.2 Synthetic Biologics Business Overview
6.3.3 Synthetic Biologics Microbiome Therapeutics Revenue, Global Share and Gross Margin (2019-2024)
6.3.4 Synthetic Biologics Microbiome Therapeutics Product Portfolio
6.3.5 Synthetic Biologics Recent Developments
6.4 Interxon
6.4.1 Interxon Comapny Information
6.4.2 Interxon Business Overview
6.4.3 Interxon Microbiome Therapeutics Revenue, Global Share and Gross Margin (2019-2024)
6.4.4 Interxon Microbiome Therapeutics Product Portfolio
6.4.5 Interxon Recent Developments
6.5 PureTech
6.5.1 PureTech Comapny Information
6.5.2 PureTech Business Overview
6.5.3 PureTech Microbiome Therapeutics Revenue, Global Share and Gross Margin (2019-2024)
6.5.4 PureTech Microbiome Therapeutics Product Portfolio
6.5.5 PureTech Recent Developments
6.6 Synlogic
6.6.1 Synlogic Comapny Information
6.6.2 Synlogic Business Overview
6.6.3 Synlogic Microbiome Therapeutics Revenue, Global Share and Gross Margin (2019-2024)
6.6.4 Synlogic Microbiome Therapeutics Product Portfolio
6.6.5 Synlogic Recent Developments
6.7 Enterome BioScience
6.7.1 Enterome BioScience Comapny Information
6.7.2 Enterome BioScience Business Overview
6.7.3 Enterome BioScience Microbiome Therapeutics Revenue, Global Share and Gross Margin (2019-2024)
6.7.4 Enterome BioScience Microbiome Therapeutics Product Portfolio
6.7.5 Enterome BioScience Recent Developments
6.8 4D Pharma
6.8.1 4D Pharma Comapny Information
6.8.2 4D Pharma Business Overview
6.8.3 4D Pharma Microbiome Therapeutics Revenue, Global Share and Gross Margin (2019-2024)
6.8.4 4D Pharma Microbiome Therapeutics Product Portfolio
6.8.5 4D Pharma Recent Developments
6.9 Second Genome
6.9.1 Second Genome Comapny Information
6.9.2 Second Genome Business Overview
6.9.3 Second Genome Microbiome Therapeutics Revenue, Global Share and Gross Margin (2019-2024)
6.9.4 Second Genome Microbiome Therapeutics Product Portfolio
6.9.5 Second Genome Recent Developments
6.10 AOBiome
6.10.1 AOBiome Comapny Information
6.10.2 AOBiome Business Overview
6.10.3 AOBiome Microbiome Therapeutics Revenue, Global Share and Gross Margin (2019-2024)
6.10.4 AOBiome Microbiome Therapeutics Product Portfolio
6.10.5 AOBiome Recent Developments
6.11 C3 Jian
6.11.1 C3 Jian Comapny Information
6.11.2 C3 Jian Business Overview
6.11.3 C3 Jian Microbiome Therapeutics Revenue, Global Share and Gross Margin (2019-2024)
6.11.4 C3 Jian Microbiome Therapeutics Product Portfolio
6.11.5 C3 Jian Recent Developments
6.12 Rebiotix
6.12.1 Rebiotix Comapny Information
6.12.2 Rebiotix Business Overview
6.12.3 Rebiotix Microbiome Therapeutics Revenue, Global Share and Gross Margin (2019-2024)
6.12.4 Rebiotix Microbiome Therapeutics Product Portfolio
6.12.5 Rebiotix Recent Developments
6.13 MicroBiome Therapeutics LLC
6.13.1 MicroBiome Therapeutics LLC Comapny Information
6.13.2 MicroBiome Therapeutics LLC Business Overview
6.13.3 MicroBiome Therapeutics LLC Microbiome Therapeutics Revenue, Global Share and Gross Margin (2019-2024)
6.13.4 MicroBiome Therapeutics LLC Microbiome Therapeutics Product Portfolio
6.13.5 MicroBiome Therapeutics LLC Recent Developments
6.14 Metabiomics
6.14.1 Metabiomics Comapny Information
6.14.2 Metabiomics Business Overview
6.14.3 Metabiomics Microbiome Therapeutics Revenue, Global Share and Gross Margin (2019-2024)
6.14.4 Metabiomics Microbiome Therapeutics Product Portfolio
6.14.5 Metabiomics Recent Developments
6.15 Ritter Pharmaceuticals
6.15.1 Ritter Pharmaceuticals Comapny Information
6.15.2 Ritter Pharmaceuticals Business Overview
6.15.3 Ritter Pharmaceuticals Microbiome Therapeutics Revenue, Global Share and Gross Margin (2019-2024)
6.15.4 Ritter Pharmaceuticals Microbiome Therapeutics Product Portfolio
6.15.5 Ritter Pharmaceuticals Recent Developments
6.16 Symberix
6.16.1 Symberix Comapny Information
6.16.2 Symberix Business Overview
6.16.3 Symberix Microbiome Therapeutics Revenue, Global Share and Gross Margin (2019-2024)
6.16.4 Symberix Microbiome Therapeutics Product Portfolio
6.16.5 Symberix Recent Developments
6.17 OpenBiome
6.17.1 OpenBiome Comapny Information
6.17.2 OpenBiome Business Overview
6.17.3 OpenBiome Microbiome Therapeutics Revenue, Global Share and Gross Margin (2019-2024)
6.17.4 OpenBiome Microbiome Therapeutics Product Portfolio
6.17.5 OpenBiome Recent Developments
6.18 Azitra
6.18.1 Azitra Comapny Information
6.18.2 Azitra Business Overview
6.18.3 Azitra Microbiome Therapeutics Revenue, Global Share and Gross Margin (2019-2024)
6.18.4 Azitra Microbiome Therapeutics Product Portfolio
6.18.5 Azitra Recent Developments
6.19 Symbiotix Biotherapies
6.19.1 Symbiotix Biotherapies Comapny Information
6.19.2 Symbiotix Biotherapies Business Overview
6.19.3 Symbiotix Biotherapies Microbiome Therapeutics Revenue, Global Share and Gross Margin (2019-2024)
6.19.4 Symbiotix Biotherapies Microbiome Therapeutics Product Portfolio
6.19.5 Symbiotix Biotherapies Recent Developments
6.20 Osel
6.20.1 Osel Comapny Information
6.20.2 Osel Business Overview
6.20.3 Osel Microbiome Therapeutics Revenue, Global Share and Gross Margin (2019-2024)
6.20.4 Osel Microbiome Therapeutics Product Portfolio
6.20.5 Osel Recent Developments
6.21 Metabogen
6.21.1 Metabogen Comapny Information
6.21.2 Metabogen Business Overview
6.21.3 Metabogen Microbiome Therapeutics Revenue, Global Share and Gross Margin (2019-2024)
6.21.4 Metabogen Microbiome Therapeutics Product Portfolio
6.21.5 Metabogen Recent Developments
7 North America
7.1 North America Microbiome Therapeutics Market Size Growth Rate (CAGR) by Country: 2019 VS 2023 VS 2030
7.2 North America Microbiome Therapeutics Market Size by Country (2019-2024)
7.3 North America Microbiome Therapeutics Market Size Forecast by Country (2025-2030)
8 Europe
8.1 Europe Microbiome Therapeutics Market Size Growth Rate (CAGR) by Country: 2019 VS 2023 VS 2030
8.2 Europe Microbiome Therapeutics Market Size by Country (2019-2024)
8.3 Europe Microbiome Therapeutics Market Size Forecast by Country (2025-2030)
9 Asia-Pacific
9.1 Asia-Pacific Microbiome Therapeutics Market Size Growth Rate (CAGR) by Country: 2019 VS 2023 VS 2030
9.2 Asia-Pacific Microbiome Therapeutics Market Size by Country (2019-2024)
9.3 Asia-Pacific Microbiome Therapeutics Market Size Forecast by Country (2025-2030)
10 Latin America
10.1 Latin America Microbiome Therapeutics Market Size Growth Rate (CAGR) by Country: 2019 VS 2023 VS 2030
10.2 Latin America Microbiome Therapeutics Market Size by Country (2019-2024)
10.3 Latin America Microbiome Therapeutics Market Size Forecast by Country (2025-2030)
11 Middle East & Africa
11.1 Middle East & Africa Microbiome Therapeutics Market Size Growth Rate (CAGR) by Country: 2019 VS 2023 VS 2030
11.2 Middle East & Africa Microbiome Therapeutics Market Size by Country (2019-2024)
11.3 Middle East & Africa Microbiome Therapeutics Market Size Forecast by Country (2025-2030)
12 Concluding Insights
13 Appendix
13.1 Reasons for Doing This Study
13.2 Research Methodology
13.3 Research Process
13.4 Authors List of This Report
13.5 Data Source
13.5.1 Secondary Sources
13.5.2 Primary Sources

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook
Cookie Settings